Lawsuit Against RB Health Highlights False Advertising Concerns
A proposed class action lawsuit against RB Health (US) LLC emphasizes ongoing issues with misleading front-of-pack nutrient claims on dietary supplements. The case, filed in the US District Court for the Central District of California, targets Airborne products, alleging that labels may mislead consumers regarding the vitamin C content in each chewable tablet, gummy, or effervescent tablet.
Key Points of the Complaint
-
Misleading Labels: The lawsuit claims that consumers might believe the amount of vitamin C displayed on the packaging applies to individual servings rather than the total amount for multiple tablets.
-
Product Coverage: The complaint includes labeling issues with six Airborne products, like Vitamin C chewable tablets and immune support gummies.
-
Consumer Perception: The plaintiff asserts that “reasonable consumers” are under the impression that each individual tablet contains the full advertised dosage of vitamin C, leading to misunderstandings about the actual content per serving.
-
Financial Impact: The lawsuit contends that consumers may be overpaying for the products, receiving far less vitamin C than they expect while still paying the full price.
Legal Basis
The suit alleges violations of California’s Unfair Competition Law, False Advertising Law, and Consumer Legal Remedies Act. It seeks class certification, restitution, injunctive relief, and changes to labeling practices.
Distinction Between Compliance and Consumer Interpretation
Industry attorney Jennifer Adams noted that this case highlights the difference between meeting regulatory standards and addressing consumer perceptions. While companies might comply with FDA regulations, how consumers interpret front-of-pack claims can differ, leading to potential legal challenges.
Moving Forward
Adams suggests that manufacturers can take practical steps to mitigate the risk of litigation while maintaining compliant labels. Simple modifications like specifying “per serving” and clarifying the number of servings can potentially address consumer misunderstandings and future legal issues.
RB Health has chosen not to comment on the ongoing litigation.
